Six months into Donald Trump’s second term, his administration is at war with the federal judiciary, evading court orders ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

Are women somehow missing from the future of innovation? New research suggests that gender bias may be quietly shaping the ...

“Stratus,” originally known as Variant XFG, is the second most prominent strain of COVID in the United States. According to ...

The suspected gunman in the attack that killed a police officer near the Emory University campus and the CDC's headquarters ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

The rapid rise of the SARS-CoV-2 variant XFG this summer could make it the dominant strain by the start of the fall COVID ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...